

April 30, 2024

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on April 30, 2024

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, April 30, 2024, *inter-alia* considered and unanimously:

1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2024. Copy of the same is enclosed along with the Report of the Auditors thereon and a declaration stating that the said report is with unmodified opinion.
2. Recommended equity dividend of Rs. 16 per share of Rs. 8/- each (200 %) for the financial year ended March 31, 2024, which will be paid to the shareholders within 30 days of declaration of the same at the ensuing Annual General Meeting.
3. Approved the Audited Financial Statements of the Company, for the year ended March 31, 2024.
4. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Mr. Anil Matai (DIN: 03122685), as an Additional Director in the capacity of Non-Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution – Refer Annexure A.
5. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Mr. Hiten Kotak (DIN: 00191115), as an Additional Director in the capacity of Non-Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution – Refer Annexure B.
6. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Ms. Radhika Gupta (DIN: 02657595), as an Additional Director in the capacity of Non-Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution – Refer Annexure C.



7. Considered on recommendation of the Nomination and Remuneration Committee, appointment of Mr. Sachin Nandgaonkar (DIN: 03410739), Non-Executive, Non – Independent Director as Non – Executive, Independent Director of the Company for a period of five years w.e.f. April 30, 2024, till April 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution – Refer Annexure D.
8. Recommended re-appointment of Mr. Bhaskar Iyer (DIN: 00480341) as Non-Executive, Independent Director of the Company, for a second term effective from October 30, 2024 till October 29, 2029, not liable to retire by rotation, subject to approval of shareholders by way of special resolution – Refer Annexure E.
9. Reconstituted the following committees of the Board:

Audit Committee		
1.	Mr. Mahesh Gupta	Chairman
2.	Mr Narendra Ambwani	Member
3.	Mr. Bhaskar Iyer	Member
4.	Mr. Rajat Bhargava	Member
5.	Mr. Hiten Kotak	Member
6.	Mr. Anil Matai	Member

Nomination and Remuneration Committee		
1.	Dr. Lalit S. Kanodia	Chairman
2.	Mr. Mahesh Gupta	Member
3.	Mr. Bhaskar Iyer	Member
4.	Mr. Rajat Bhargava	Member
5.	Mr. Sachin Nandgaonkar	Member
6.	Ms. Radhika Gupta	Member

Sustainability and Corporate Social Responsibility Committee		
1.	Mr. Narendra Ambwani	Chairman
2.	Ms. Z. Khorakiwala	Member
3.	Mr. Sachin Nandgaonkar	Member
4.	Mr. Yugal Sikri	Member
5.	Ms. Radhika Gupta	Member

Stakeholders' Relationship Committee		
1.	Mr. Narendra Ambwani	Chairman
2.	Mr. Mahesh Gupta	Member
3.	Mr. Yugal Sikri	Member
4.	Ms. Radhika Gupta	Member
5.	Mr. Anil Matai	Member

Risk Management Committee		
1.	Mr. Mahesh Gupta	Chairman
2.	Mr. Bhaskar Iyer	Member
3.	Mr. Rajat Bhargava	Member
4.	Mr. Hiten Kotak	Member
5.	Mr. Anil Matai	Member

The disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 and pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed herewith.

The meeting commenced at 03:00 p.m. and concluded at 6.45 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
 For RPG Life Sciences Limited
 RAJESH RAMESH Digitally signed by RAJESH RAMESH SHIRAMBEKAR
 SHIRAMBEKAR Date: 2024.04.30 18:49:30 +05'30'
 Rajesh Shirambekar
 Head – Legal & Company Secretary



(Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

Annexure – A

- 1) Appointment of Mr. Anil Matai (DIN: 03122685) as an Additional Independent Director:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as an Additional Director in the capacity of Non-Executive, Independent Director.
2	Date of re-appointment	April 30, 2024
	Term of re-appointment	Appointed for a period of 5 years subject to approval of the shareholders by way of special resolution
3	Brief Profile (in case of appointment)	<p>Mr. Anil Matai has over 30 years of progressive experience in the Life Sciences space across MNCs, Start-up & leading Indian firms. His vast experience includes spearheading operations across Zydus Healthcare Ltd, Novartis India Ltd, GSK India, and Global Pharma, Dubai.</p> <p>After superannuating as Managing Director of Zydus Healthcare Ltd, Mr. Matai was engaged as Senior Advisor - Life Sciences at IQVIA Consulting and is currently Director General of the Organisation of Pharmaceutical Producers of India (OPPI). Mr. Matai has functioned on the boards of Zydus Healthcare Ltd., Bayer Zydus Pharma Private Ltd., Novartis Healthcare Private Ltd and Biochem Pharmaceutical Industries Ltd.</p> <p>As a strategic collaborator, he interfaces with Board of Directors and relevant stakeholders to position business growth and operational ingenuity. Mr. Matai has proven expertise in General Management with demonstrated ability to build new business models, cultivate relationships and grow profitably in highly competitive markets through effective planning, strategic direction & team development for product launch, promotional support, sales force development, Business Development and P&L accountability across multiple functions.</p> <p>Mr. Matai is a Mechanical Engineer from MNIT, Jaipur with a Post Graduate Diploma in International Trade from IIFT Delhi. Mr. Matai has attended Management Development Programs at Harvard Business School and at IMD, Switzerland.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Anil Matai is not related to any Director or Key Managerial Personnel of the Company.



5	Affirmation	As per declaration submitted to the Company, Mr. Matai has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
---	-------------	---

Annexure – B

2) Appointment of Mr. Hiten Kotak (DIN: 00191115) as an Additional Independent Director:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as an Additional Director in the capacity of Non-Executive, Independent Director.
2	Date of re-appointment	April 30, 2024
	Term of re-appointment	Appointed for a period of 5 years subject to approval of the shareholders by way of special resolution
3	Brief Profile (in case of appointment)	<p>Mr. Hiten Kotak is an Executive Director in the Transaction Tax, Private Client, and Corporate Restructuring practice groups in the Mumbai office of M/s Khaitan & Co. Before joining the Firm, Hiten was leading the Mergers & Acquisition Tax practice at Price Waterhouse & Co. LLP (PwC), Mumbai.</p> <p>With over three decades of experience as a Chartered Accountant, Mr. Kotak has been advising clients on structuring mergers, acquisitions, and other cross-border transactions involving reorganization, divestment, minority buyouts, and joint ventures arising from domestic and cross-border transactions. He has also advised HNIs and credible business groups on their wealth, estate, and succession planning strategies.</p> <p>Mr. Kotak is a well-regarded professional and is recognized for his work and contribution to the business community. He has authored/ co-authored several articles and papers in his areas of interest and expertise.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Hiten Kotak is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Mr. Kotak has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.



Annexure – C

3) Appointment of Ms. Radhika Gupta (DIN: 02657595) as an Additional Independent Director:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as an Additional Director in the capacity of Non-Executive, Independent Director.
2	Date of re-appointment	April 30, 2024
	Term of re-appointment	Appointed for a period of 5 years subject to approval of the shareholders by way of special resolution
3	Brief Profile (in case of appointment)	<p>Ms. Radhika Gupta has graduated from The Jerome Fisher Program in Management and Technology (5 year Joint Degree Program), University of Pennsylvania, Philadelphia. She has completed her B.S. in Economics (Finance and Management) from The Wharton School, B.S. in Engineering (Computer Science Engineering) from The Moore School and Minor in Mathematics from the College of Arts and Sciences.</p> <p>Ms. Gupta started her career at McKinsey & Company, New Jersey, U.S.A. as a Business Analyst, from 2005 to 2006. Post this, She was a part of the Global Asset Allocation team at AQR Capital, Greenwich, U.S.A., as Portfolio Manager. She was also one of the founding members of Forefront Capital Management Pvt. Ltd., a public market alternative asset management firm from 2009 to 2014. Since February 2017, Ms. Gupta has taken over as the CEO of Edelweiss Asset Management Limited and has been instrumental in the successful run of the investment management business.</p> <p>Ms. Gupta has been an influential figure on the board of the Association of Mutual Funds in India (AMFI) since 2017 and served as the Vice Chairperson for two consecutive terms from 2021 to 2023. Her insights and leadership have been integral to the industry's growth and innovation.</p> <p>Ms. Gupta has been awarded with a slew of prestigious awards viz. "The Economic Times 40 Under 40 Business Leaders Award, Business Today's Most Powerful Women in Indian Business Award, Fortune India's 50 Most Powerful Women in Business Forbes Women Power's Self-Made Women accolade" and she</p>



		was further distinguished as a Young Global Leader in 2022 by the World Economic Forum.
4	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Radhika Gupta is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Ms. Gupta has confirmed that she is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Annexure – D

4) Appointment of Mr. Sachin Nandgaonkar (DIN: 03410739) as an Independent Director:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as an Independent Director of the Company.
2	Date of re-appointment	April 30, 2024
	Term of re-appointment	Appointed for a period of 5 years subject to approval of the shareholders by way of special resolution
3	Brief Profile (in case of appointment)	Mr. Sachin Nandgaonkar, was a member of the Management Board of RPG Group. During his tenure with the RPG Group, he was Sector Head for the Specialty Sector comprising of RPG Life Sciences and Raychem RPG. He was also responsible for evangelizing RPG's efforts in Digital, Business Excellence, Innovation and New Ventures. Prior to joining RPG Group in Jan 2015, he had spent 22 years in management consulting across Boston Consulting Group and Accenture." Mr. Nandgaonkar is B.Tech. in Electrical Engineering from IIT, Bombay and MBA from IIM, Ahmedabad.
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Sachin Nandgaonkar is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Mr. Nandgaonkar has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Annexure – E

5) Appointment of Mr. Bhaskar Iyer (DIN: 00480341) as an Independent Director for second consecutive term of five years:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment as an Independent Director of the Company.
---	---	---



2	Date of re-appointment	Re-appointment of Mr. Bhaskar Iyer as an Independent Director of the Company from October 30, 2024.
	Term of re-appointment	Mr. Iyer has been re-appointed for a period of 5 (five) consecutive years from October 30, 2024 to October 29, 2029 subject to approval of shareholders at the ensuing Annual General Meeting.
3	Brief Profile (in case of appointment)	<p>Mr. Bhaskar Iyer is a strategic business leader with over 40 years of experience in pharmaceutical and healthcare industry spanning country management, global leadership and Board Directorship. Mr. Iyer worked for Abbott as Vice President, and was Abbott Management Representative for India responsible for overall pharmaceuticals business in the Country, managing teams comprising of MDs and Function Heads. Mr. Iyer managed a team of 12000 employees and a turnover of a billion dollars. Prior to joining Abbott, Mr. Iyer was the President (India and Emerging Markets) with Wockhardt Limited. Mr. Iyer has held global leadership positions with AstraZeneca in Asia-Pacific based at Singapore and country management positions in AstraZeneca, Nicholas Piramal India Limited, ICI Pharmaceuticals and progressively senior roles in Glaxo India Limited.</p> <p>Mr. Iyer is currently working as Operating Partner in Advent International, a global private equity firm and is on Governance and Advisory Board of start-up Companies. Mr. Iyer is on the Board of Pharmarack Technologies Pvt. Ltd. , Bharat Serums and Vaccines Ltd, ZCL Chemicals Limited, Themis Medicare Limited and Cohance Lifesciences Limited as a Non-Executive Director. He also works as an Operating Advisor for Quadria Capital, a Singapore headquartered healthcare-focussed PE firm.</p> <p>Mr. Iyer holds a bachelor's degree in Science and MBA in Marketing Management from the Bombay University.</p> <p>Mr. Iyer is a prolific reader and also enjoys travelling and discovering new places</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Bhaskar Iyer is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Mr. Iyer has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.



Independent Auditor's Report on the Quarterly and Year to Date Audited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
**The Board of Directors of
RPG Life Sciences Limited**

Report on the audit of the Financial Results**Opinion**

We have audited the accompanying statement of quarterly and year to date financial results of RPG Life Sciences Limited (the "Company") for the quarter ended March 31, 2024 and for the year ended March 31, 2024 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2024 and for the year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



S R B C & CO LLP

Chartered Accountants

Other Matter

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

Aruna

per Aruna Kumaraswamy

Partner

Membership No.: 219350

UDIN:24219350BKCSU05688

Place: Mumbai

Date: April 30, 2024



STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2024

Particulars	(Rs. in Lakhs)				
	Quarter ended			Year ended	
	31-03-2024	31-12-2023	31-03-2023	31-03-2024	31-03-2023
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from Operations	12,699	15,370	11,849	58,205	51,281
2 Other Income	165	192	184	721	480
3 Total Income (1+2)	12,864	15,562	12,033	58,926	51,761
4 Expenses					
(a) Cost of Materials Consumed	2,803	2,485	2,242	12,065	8,612
(b) Purchases of Stock-in-Trade	1,492	1,649	2,026	6,118	9,205
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(151)	683	(319)	270	(730)
(d) Employee Benefits Expense	3,208	3,369	3,377	13,215	11,706
(e) Finance Costs	14	14	5	45	31
(f) Depreciation and Amortisation Expense	449	414	389	1,707	1,550
(g) Other Expenses	3,275	3,394	2,932	13,722	12,219
Total Expenses	11,090	12,008	10,652	47,142	42,593
5 Profit before tax (3-4)	1,774	3,554	1,381	11,784	9,168
6 Income tax expenses					
a. Current Tax	545	950	369	3,254	2,435
b. Deferred Tax	(95)	(42)	(23)	(236)	(31)
Total tax expenses	450	908	346	3,018	2,404
7 Profit for the period (5-6)	1,324	2,646	1,035	8,766	6,764
8 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit or Loss	(82)	2	36	(75)	9
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	22	(1)	(9)	19	(2)
Other Comprehensive Income Net of Tax	(60)	1	27	(56)	7
9 Total Comprehensive Income for the period (7+8)	1,264	2,647	1,062	8,710	6,771
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
11 Other Equity				36,162	29,437
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					
(a) Basic (in Rs.)	8.01	16.00	6.26	53.01	40.90
(b) Diluted (in Rs.)	8.01	16.00	6.26	53.01	40.90

SIGNED FOR IDENTIFICATION
 BY 
 S R B C & CO LLP
 MUMBAI



Audited Balance Sheet as at March 31, 2024		
Particulars	(Rs. in Lakhs)	
	As at March 31, 2024 Audited	As at March 31, 2023 Audited
ASSETS		
Non-current assets		
Property, plant and equipment (including Right of use assets)	9,703	10,127
Capital work-in-progress	8,478	1,503
Other intangible assets	1,650	2,299
Intangible assets under development	1,153	1,041
Financial assets		
i. Investments	101	-
ii. Loans	19	18
iii. Other financial assets	43	44
Income Tax asset (Net)	122	173
Deferred tax assets (Net)	58	-
Other non-current assets	151	325
Total non-current assets	21,478	15,530
Current assets		
Inventories	10,100	9,505
Financial assets		
i. Investments	9,015	5,843
ii. Loans	-	2
iii. Trade receivables	4,913	3,743
iv. Cash and cash equivalents	1,972	2,482
v. Bank balances other than (iv) above	1,675	3,222
vi. Other financial assets	103	135
Other current assets	2,031	1,473
Total current assets	29,809	26,405
Total assets	51,287	41,935
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity	36,162	29,437
Total equity	37,485	30,760
LIABILITIES		
Non-current liabilities		
Financial liabilities		
i. Other financial liabilities	303	302
Provisions	403	398
Deferred tax liabilities (Net)	-	197
Total non-current liabilities	706	897
Current liabilities		
Financial liabilities		
i. Borrowings	-	1
ii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	503	482
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	6,599	5,987
iii. Other financial liabilities	3,982	2,002
Provisions	1,217	1,186
Income tax liabilities (Net)	272	-
Other current liabilities	523	620
Total current liabilities	13,096	10,278
Total liabilities	13,802	11,175
Total equity and liabilities	51,287	41,935

SIGNED FOR IDENTIFICATION
 BY 
 S R B C & CO LLP
 MUMBAI



Audited statement of cash flows for the year ended March 31, 2024

(Rs. in Lakhs)

Particulars	For the Year ended March 31, 2024	For the Year ended March 31, 2023
	Audited	Audited
A Cash Flow from operating activities		
Profit before income tax	11,784	9,168
Adjustments for		
Depreciation and amortisation expenses	1,707	1,550
Finance costs	45	31
Profit on disposal of property, plant and equipment	(1)	78
Unrealised exchange rate difference	(10)	46
Provision for Doubtful Debts and Advances (Net)	270	50
Interest received	(142)	(273)
Provisions no longer required and written back	-	(7)
Fair value gain arising on financial assets measured at fair value through profit and loss(net)	(472)	(144)
Gain on sale of investments	(105)	-
	13,076	10,499
Working capital adjustments:		
(Increase) in trade receivables	(1,425)	(540)
Decrease / (Increase) in financial assets - Loans	2	(8)
Decrease in other financial assets	32	14
(Increase) / Decrease in other current assets	(558)	443
(Increase) in inventories	(595)	(1,206)
Increase in trade payables	633	1,926
Increase in other financial liabilities	1,338	539
(Decrease) in provisions	(39)	(126)
(Decrease) / Increase in other current liabilities	(97)	63
Cash generated from operations	12,367	11,605
Income taxes paid	(2,931)	(2,523)
Net cash inflow from operating activities	9,436	9,082
B Cash flow from investing activities:		
Acquisition of property, plant and equipment and Intangible assets	(6,923)	(3,273)
Proceeds from sale of property, plant and equipment and Intangible assets	15	8
Movement in Other bank balances (Net)	1,547	(1,890)
Investment in Mutual Funds	(4,350)	(5,699)
Proceeds from sale of Mutual fund	1,755	-
Investment in unquoted equity shares	(101)	-
Interest received	142	273
Net cash (outflow) from investing activities	(7,915)	(10,581)
C Cash flow from financing activities		
(Repayment of) long term borrowings	(1)	(1)
(Repayment of) Short-term Borrowings	-	(27)
Interest paid	(45)	(27)
Repayment of principal portion of lease liability	-	(65)
Interest paid on lease liability	-	(4)
Dividend paid	(1,985)	(1,588)
Net cash (outflow) from financing activities	(2,031)	(1,712)
Net (decrease)/increase in cash and cash equivalents	(510)	(3,212)
Add: Cash and cash equivalents at the beginning of the financial year	2,482	5,694
Cash and cash equivalents at the end of the year	1,972	2,482

SIGNED FOR IDENTIFICATION
 BY 
 S R B C & CO LLP
 MUMBAI



Notes:

1. The above results have been reviewed and recommended by the Audit Committee at its meeting held on April 29, 2024 and have been approved by the Board of Directors at its meeting held on April 30, 2024.
2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
3. Figures of the quarter ended March 31, 2024 and March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the relevant financial year which were subjected to limited review by Auditors.
4. The Board of Directors has recommended a final dividend of Rs.16 (Rupees Sixteen only) per equity share (200% on the face value of Rs 8 each) for the financial year 2023-24, subject to the approval of shareholders at the ensuing Annual General Meeting.

For RPG Life Sciences Limited



Yugal Sikri
Managing Director
Mumbai, April 30, 2024





RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

April 30, 2024

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of the provisions of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby state that the Statutory Auditors of the Company M/s. SRBC & Co. LLP (Firm's Registration No. 324982E/E300003) have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2024.

Kindly take this declaration on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Vishal Shah
Chief Financial Officer

